Silence TherapeuticsSLN
About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
Employees: 109
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
11% more funds holding
Funds holding: 63 [Q1] → 70 (+7) [Q2]
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
0.6% more ownership
Funds ownership: 19.98% [Q1] → 20.58% (+0.6%) [Q2]
10% less capital invested
Capital invested by funds: $591M [Q1] → $532M (-$59.2M) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q1] → 6 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Morgan Stanley Michael Ulz 46% 1-year accuracy 6 / 13 met price target | 172%upside $49 | Overweight Reiterated | 8 Oct 2024 |
HC Wainwright & Co. Patrick Trucchio 34% 1-year accuracy 31 / 91 met price target | 317%upside $75 | Buy Reiterated | 30 Aug 2024 |
Chardan Capital Keay Nakae 54% 1-year accuracy 15 / 28 met price target | 206%upside $55 | Buy Maintained | 16 Aug 2024 |